Abstract
Dasatinib is a potent second-generation tyrosine kinase inhibitor approved for the treatment of chronic myeloid leukemia after imatinib failure. However, some patients treated with dasatinib experience pleural effusions (PEs). The determinants of pleural effusion in long-term dasatinib treatment (median 35 months, range 1–55) were investigated in single-center data of 65 patients enrolled in global phase 2 and phase 3 trials. Of the 65 patients, 35 (54%) developed dasatinib-induced pleural effusion (a median onset time, 20 months; range 0.2–54). The first pleural effusion developed in 15 (43%) patients within 12 months of dasatinib therapy. Disease phase (P = 0.02), dose schedule (P = 0.002) and actual daily mean dose (P = 0.0002) were significantly associated with an increased risk of pleural effusion. Twice-daily administration of dasatinib resulted in significantly more patients developing pleural effusions compared with the once-daily dosing schedule, particularly in advanced disease. In addition, a strong correlation was found between actual daily mean dose and time to onset of pleural effusions in patients treated with a daily mean dose >100 mg/day of dasatinib (P = 0.01). These data emphasize the need for dasatinib dose and schedule optimization and long-term monitoring of dasatinib-treated patients to prevent the negative clinical implications of pleural effusion.
Similar content being viewed by others
References
Hochhaus A, Kreil S, Corbin AS, La Rosée P, Müller MC, Lahaye T, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 2002;16:2190–6.
Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2002;2:117–25.
O’Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005;65:4500–5.
Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004;47:6658–61.
O’Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood. 2007;110:2242–9.
Cortes J, Rousselot P, Kim DW, Ritchie E, Hamerschlak N, Coutre S, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood. 2007;109:3207–13.
Guilhot F, Apperley J, Kim DW, Bullorsky EO, Baccarani M, Roboz GJ, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood. 2007;109:4143–50.
Kantarjian H, Pasquini R, Hamerschlak N, Rousselot P, Holowiecki J, Jootar S, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood. 2007;109:5143–50.
Hochhaus A, Baccarani M, Deininger M, Apperley J, Lipton J, Goldberg S, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 2008;22:1200–6.
Quintás-Cardama A, Kantarjian H, O’Brien S, Borthakur G, Bruzzi J, Munden R, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol. 2007;25:3908–14.
de Lavallade H, Punnialingam S, Milojkovic D, Bua M, Khorashad JS, Gabriel IH, et al. Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. Br J Haematol. 2008;141:745–7.
Kantarjian H, Cortes J, Kim DW, Dorlhiac-Llacer P, Pasquini R, DiPersio J, et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood. 2009;113:6322–9.
Shah NP, Kantarjian HM, Kim DW, Réa D, Dorlhiac-Llacer PE, Milone JH, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol. 2008;26:3204–12.
National Cancer Institute, Cancer Therapy Evaluation Program. Common terminology criteria for adverse events, version 3.0. DCTD, NCI, NIH. 2007. http://ctep.cancer.gov. Accessed 9 June 2007.
Bristol-Myers Squibb Company. Sprycel® (dasatinib) package insert. Princeton: Bristol-Myers; 2010.
Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362:2260–70.
Wang X, Hochhaus A, Kantarjian HM, Agrawal S, Roy A, Pfister M, et al. Dasatinib pharmacokinetics and exposure-response (E-R): relationship to safety and efficacy in patients (pts) with chronic myeloid leukemia (CML). Blood. 2008;26:175s (abstract 3590).
Jayson GC, Parker GJ, Mullamitha S, Valle JW, Saunders M, Broughton L, et al. Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab’, leads to fluid accumulation and is associated with increased tumor vascularized volume. J Clin Oncol. 2005;23:973–81.
Bergeron A, Bergot E, Vilela G, Ades L, Devergie A, Espérou H, et al. Hypersensitivity pneumonitis related to imatinib mesylate. J Clin Oncol. 2002;20:4271–2.
Goldblatt M, Huggins JT, Doelken P, Gurung P, Sahn S. Dasatinib-induced pleural effusions: a lymphatic network disorder? Am J Med Sci. 2009;338:414–7.
Latagliata R, Breccia M, Vigneri P, Luciano L, Gozzini A, Castagnetti F, et al. Occurrence of pleural effusions during dasatinib treatment in elderly CML patients. Haematol. 2010;95:339 (abstract 0811).
Acknowledgments
This study was supported by research grants from Bristol-Myers Squibb, the Korea Health 21 R&D Project, Ministry of Health and Welfare, Republic of Korea (01-PJ10-PG6-01GN16-0005) and from the Basic Research Program of the Korea Science and Engineering Foundation (R21-2007-000-10041-0) (2007). We thank Daniel Hutta, PhD, and Candice Willmon, PhD, for medical editorial assistance with this manuscript.
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
12185_2011_921_MOESM2_ESM.jpg
Effect of administration schedule on cumulative incidence of pleural effusion in CP only (a), in AP only (b), and in BC only (c). AP, accelerated phase; BC, blast crisis; BID, twice daily; CP, chronic phase; QD, once daily (JPEG 34 kb)
12185_2011_921_MOESM3_ESM.jpg
Effect of actual daily mean dose on cumulative percentage of pleural effusion development during dasatinib therapy in CP only (a), in AP only (b, and in BC only (c) (JPEG 39 kb)
12185_2011_921_MOESM4_ESM.jpg
Event-free survival of patients with or without pleural effusion in all disease phases (a) and in chronic phase (b). Events include death, disease progression, loss of complete hematologic response and loss of major cytogenetic response (JPEG 28 kb)
About this article
Cite this article
Kim, D., Goh, HG., Kim, SH. et al. Long-term pattern of pleural effusion from chronic myeloid leukemia patients in second-line dasatinib therapy. Int J Hematol 94, 361–371 (2011). https://doi.org/10.1007/s12185-011-0921-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12185-011-0921-9